GSK Responds To NICE's 2nd Technology Appraisal Consultation Document On The Use Of T
 

The draft recommendations announced today by NICE in the second technology appraisal consultation document (ACD) suggest that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. "Given our involvement, it is difficult to comment without the appearance of self interest, however we strongly believe that the wrong decision has been made for patients, doctors and the NHS," said Simon Jose, General Manager for GSK UK Pharmaceuticals.

More...